share_log

SVB Leerink Downgrades Global Blood Therapeutics to Market Perform, Announces $68.5 Price Target

SVB Leerink Downgrades Global Blood Therapeutics to Market Perform, Announces $68.5 Price Target

SVB Leerink 将全球血液疗法的评级下调至市场表现,宣布目标股价为68.5美元
Benzinga Real-time News ·  2022/08/09 06:38

SVB Leerink analyst Andrew Berens downgrades Global Blood Therapeutics (NASDAQ:GBT) from Outperform to Market Perform and announces $68.5 price target.

SVB Leerink分析师安德鲁·贝伦斯将Global Blood Therapeutics(纳斯达克股票代码:GBT)的评级从跑赢大盘下调至市场表现,并宣布目标股价为68.5美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发